25 XP   0   0   10

Cellectar Biosciences Inc
Buy, Hold or Sell?

Let's analyse Cellectar together

PenkeI guess you are interested in Cellectar Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cellectar Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cellectar Biosciences Inc

I send you an email if I find something interesting about Cellectar Biosciences Inc.

Quick analysis of Cellectar (30 sec.)










What can you expect buying and holding a share of Cellectar? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$-1.09
Expected worth in 1 year
$-3.21
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-2.12
Return On Investment
-53.4%

For what price can you sell your share?

Current Price per Share
$3.98
Expected price per share
$3.15 - $6.641
How sure are you?
50%

1. Valuation of Cellectar (5 min.)




Live pricePrice per Share (EOD)

$3.98

Intrinsic Value Per Share

$-34.96 - $-18.75

Total Value Per Share

$-36.05 - $-19.83

2. Growth of Cellectar (5 min.)




Is Cellectar growing?

Current yearPrevious yearGrowGrow %
How rich?-$13.3m$23.2m-$21m-933.0%

How much money is Cellectar making?

Current yearPrevious yearGrowGrow %
Making money-$9.4m-$6.8m-$2.5m-27.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cellectar (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#972 / 1031

Most Revenue
#993 / 1031

Most Profit
#577 / 1031

Most Efficient
#447 / 1031

What can you expect buying and holding a share of Cellectar? (5 min.)

Welcome investor! Cellectar's management wants to use your money to grow the business. In return you get a share of Cellectar.

What can you expect buying and holding a share of Cellectar?

First you should know what it really means to hold a share of Cellectar. And how you can make/lose money.

Speculation

The Price per Share of Cellectar is $3.98. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cellectar.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cellectar, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.09. Based on the TTM, the Book Value Change Per Share is $-0.53 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.53 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cellectar.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.12-28.1%-0.76-19.1%-0.56-14.0%-0.47-11.9%-0.34-8.5%
Usd Book Value Change Per Share-1.05-26.3%-0.53-13.3%-0.53-13.2%-0.12-3.1%-0.04-0.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.2%0.010.2%
Usd Total Gains Per Share-1.05-26.3%-0.53-13.3%-0.53-13.2%-0.11-2.9%-0.03-0.7%
Usd Price Per Share2.64-1.93-1.28-1.64-1.91-
Price to Earnings Ratio-0.59--0.65--0.54--1.02--0.71-
Price-to-Total Gains Ratio-2.52--0.03--2.29--2.88-0.30-
Price to Book Ratio-2.43--12.50-1.01--1.43-1.16-
Price-to-Total Gains Ratio-2.52--0.03--2.29--2.88-0.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.98
Number of shares251
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.53-0.12
Usd Total Gains Per Share-0.53-0.11
Gains per Quarter (251 shares)-133.30-28.59
Gains per Year (251 shares)-533.19-114.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-533-5439-124-124
20-1066-107618-247-238
30-1600-160927-371-352
40-2133-214237-494-466
50-2666-267546-618-580
60-3199-320855-741-694
70-3732-374164-865-808
80-4265-427473-988-922
90-4799-480782-1112-1036
100-5332-534092-1235-1150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.037.00.07.5%4.071.00.05.3%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%12.028.00.030.0%25.049.01.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%2.00.038.05.0%16.00.059.021.3%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%12.028.00.030.0%26.049.00.034.7%

Fundamentals of Cellectar

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Fundamental data was last updated by Penke on 2024-03-20 13:39:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cellectar Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cellectar earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cellectar to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cellectar Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY--263.0%+263.0%
5Y--452.4%+452.4%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Cellectar is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cellectar to the Biotechnology industry mean.
  • -63.7% Return on Assets means that Cellectar generated $-0.64 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cellectar Biosciences Inc:

  • The MRQ is -63.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -70.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-63.7%TTM-70.1%+6.4%
TTM-70.1%YOY-26.1%-44.1%
TTM-70.1%5Y-31.6%-38.5%
5Y-31.6%10Y-27.4%-4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-63.7%-12.5%-51.2%
TTM-70.1%-12.2%-57.9%
YOY-26.1%-11.2%-14.9%
5Y-31.6%-13.3%-18.3%
10Y-27.4%-14.6%-12.8%
1.1.3. Return on Equity

Shows how efficient Cellectar is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cellectar to the Biotechnology industry mean.
  • 0.0% Return on Equity means Cellectar generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cellectar Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-40.5%+40.5%
TTM-40.5%YOY-34.6%-5.8%
TTM-40.5%5Y-31.0%-9.4%
5Y-31.0%10Y-38.5%+7.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.0%+16.0%
TTM-40.5%-15.8%-24.7%
YOY-34.6%-13.9%-20.7%
5Y-31.0%-18.2%-12.8%
10Y-38.5%-19.1%-19.4%

1.2. Operating Efficiency of Cellectar Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cellectar is operating .

  • Measures how much profit Cellectar makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cellectar to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cellectar Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY--280.2%+280.2%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Cellectar is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cellectar Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY-3.609-3.609
5Y-5.554-5.554
10Y-7.396-7.396

1.3. Liquidity of Cellectar Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cellectar is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.22 means the company has $1.22 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cellectar Biosciences Inc:

  • The MRQ is 1.221. The company is just able to pay all its short-term debts.
  • The TTM is 1.949. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.221TTM1.949-0.728
TTM1.949YOY5.826-3.877
TTM1.9495Y6.435-4.486
5Y6.43510Y4.947+1.488
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2213.987-2.766
TTM1.9494.440-2.491
YOY5.8265.569+0.257
5Y6.4356.158+0.277
10Y4.9476.492-1.545
1.3.2. Quick Ratio

Measures if Cellectar is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cellectar to the Biotechnology industry mean.
  • A Quick Ratio of 1.15 means the company can pay off $1.15 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cellectar Biosciences Inc:

  • The MRQ is 1.153. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.842. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.153TTM1.842-0.689
TTM1.842YOY5.672-3.830
TTM1.8425Y6.211-4.369
5Y6.21110Y4.718+1.492
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1533.653-2.500
TTM1.8424.158-2.316
YOY5.6725.515+0.157
5Y6.2116.012+0.199
10Y4.7186.206-1.488

1.4. Solvency of Cellectar Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cellectar assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cellectar to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.62 means that Cellectar assets are financed with 162.0% credit (debt) and the remaining percentage (100% - 162.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cellectar Biosciences Inc:

  • The MRQ is 1.620. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 0.870. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.620TTM0.870+0.750
TTM0.870YOY0.205+0.664
TTM0.8705Y0.319+0.551
5Y0.31910Y0.382-0.063
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6200.336+1.284
TTM0.8700.330+0.540
YOY0.2050.267-0.062
5Y0.3190.367-0.048
10Y0.3820.378+0.004
1.4.2. Debt to Equity Ratio

Measures if Cellectar is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cellectar to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cellectar Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.354-0.354
TTM0.354YOY0.275+0.079
TTM0.3545Y0.261+0.092
5Y0.26110Y0.703-0.442
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM0.3540.398-0.044
YOY0.2750.334-0.059
5Y0.2610.431-0.170
10Y0.7030.476+0.227

2. Market Valuation of Cellectar Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cellectar generates.

  • Above 15 is considered overpriced but always compare Cellectar to the Biotechnology industry mean.
  • A PE ratio of -0.59 means the investor is paying $-0.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cellectar Biosciences Inc:

  • The EOD is -0.890. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.591. Based on the earnings, the company is expensive. -2
  • The TTM is -0.645. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.890MRQ-0.591-0.300
MRQ-0.591TTM-0.645+0.055
TTM-0.645YOY-0.544-0.101
TTM-0.6455Y-1.023+0.377
5Y-1.02310Y-0.706-0.317
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.890-2.697+1.807
MRQ-0.591-2.422+1.831
TTM-0.645-2.709+2.064
YOY-0.544-4.116+3.572
5Y-1.023-6.257+5.234
10Y-0.706-6.478+5.772
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cellectar Biosciences Inc:

  • The EOD is -1.411. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.936. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.760. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.411MRQ-0.936-0.475
MRQ-0.936TTM-0.760-0.176
TTM-0.760YOY-0.635-0.125
TTM-0.7605Y-1.183+0.423
5Y-1.18310Y-2.084+0.900
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.411-3.344+1.933
MRQ-0.936-2.939+2.003
TTM-0.760-3.486+2.726
YOY-0.635-5.592+4.957
5Y-1.183-8.464+7.281
10Y-2.084-8.872+6.788
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cellectar is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -2.43 means the investor is paying $-2.43 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cellectar Biosciences Inc:

  • The EOD is -3.663. Based on the equity, the company is expensive. -2
  • The MRQ is -2.430. Based on the equity, the company is expensive. -2
  • The TTM is -12.497. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.663MRQ-2.430-1.233
MRQ-2.430TTM-12.497+10.068
TTM-12.497YOY1.010-13.508
TTM-12.4975Y-1.425-11.072
5Y-1.42510Y1.161-2.586
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.6632.198-5.861
MRQ-2.4302.042-4.472
TTM-12.4972.121-14.618
YOY1.0102.907-1.897
5Y-1.4253.682-5.107
10Y1.1614.114-2.953
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cellectar Biosciences Inc.

3.1. Institutions holding Cellectar Biosciences Inc

Institutions are holding 32.277% of the shares of Cellectar Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Nantahala Capital Management, LLC21.98150.2238270115627011560
2023-12-31AIGH Capital Management, LLC15.58572.098819152201237709182.6847
2023-12-31ADAR1 Capital Management LLC11.21461.3642137808213780820
2023-12-31Worth Venture Partners, LLC5.64691.0388693909414786148.6033
2023-12-31Vanguard Group Inc3.92970482890307006174.5503
2023-12-31Longwood Capital Partners LLC3.88580.7445477500356200293.6521
2023-12-31Geode Capital Management, LLC0.560506887060229.5818
2023-12-31BlackRock Inc0.464205704200
2023-12-31LLBH Private Wealth Management, LLC0.18720.016323000230000
2023-12-31Goss Wealth Management LLC0.1710.000721013210130
2023-12-31State Street Corporation0.127901571400
2023-12-31Morgan Stanley - Brokerage Accounts0.1225015056560.3733
2023-12-31Northern Trust Corp0.1032012686126860
2023-12-31Commerce Bank NA/MO0.09770.00021200000
2023-12-31Tower Research Capital LLC0.030.00013686-2278-38.1958
2023-12-31UBS Group AG0.009801200-56-4.4586
2023-12-31Advisor Group Holdings, Inc.0.00420521-21-3.8745
2023-12-31U.S. Bancorp0.0023028500
2023-12-31Wells Fargo & Co0.0005060-11-15.493
2023-12-31HARBOUR INVESTMENTS, INC.0.000304000
Total 64.12555.48747879930+6455350+81.9%

3.2. Funds holding Cellectar Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.9760.000136570400
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.96110.000511809977006.9747
2024-01-31Fidelity Extended Market Index0.33230.00054083000
2024-01-31Fidelity Nasdaq Composite Index0.09740.00031196400
2024-01-31Fidelity Series Total Market Index0.07720.0001949199911.764
2023-12-31Northern Trust Extended Eq Market Idx0.05980.00047353314474.6971
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05980.00047353314474.6971
2024-01-31Fidelity Total Market Index0.0460565100
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.04010.0002493200
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.037504608-95096-95.3783
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.03750.0001460800
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.03220.0002396170.177
2024-02-29Vanguard U.S. Eq Idx £ Acc0.01770.0001217900
2024-01-31Spartan Total Market Index Pool E0.01410172700
2024-02-29State St US Ttl Mkt Indx SL Cl I0.0055068000
2023-12-31SSgA U.S. Extended Market Index Class I0.00450.000154700
2024-02-29State St US Extended Mkt Indx NL Cl C0.00450.000154700
2023-12-31BNYM Mellon SL Market Completion UC10.00350.0003425-7-1.6204
2023-12-31Northern Trust Wilshire 50000.0029035700
2023-12-31NT US Market Cap Idx Fd - L0.0029035700
Total 4.81250.0034591373-80109-13.5%

3.3. Insider Transactions

Insiders are holding 3.782% of the shares of Cellectar Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2020-12-28Dov ElefantBUY74071.35
2020-12-28James V CarusoBUY370371.35
2020-12-28Jarrod LongcorBUY296301.35

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cellectar Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.049-0.531-49%-0.526-50%-0.123-88%-0.036-97%
Book Value Per Share---1.0870.184-692%1.896-157%1.592-168%1.075-201%
Current Ratio--1.2211.949-37%5.826-79%6.435-81%4.947-75%
Debt To Asset Ratio--1.6200.870+86%0.205+689%0.319+408%0.382+324%
Debt To Equity Ratio---0.354-100%0.275-100%0.261-100%0.703-100%
Dividend Per Share----0%-0%0.009-100%0.008-100%
Eps---1.118-0.761-32%-0.555-50%-0.472-58%-0.338-70%
Free Cash Flow Per Share---0.705-0.629-11%-0.459-35%-0.408-42%-0.302-57%
Free Cash Flow To Equity Per Share--1.1260.024+4507%-0.263+123%0.130+769%0.085+1223%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---18.748--------
Intrinsic Value_10Y_min---34.960--------
Intrinsic Value_1Y_max---1.308--------
Intrinsic Value_1Y_min---2.308--------
Intrinsic Value_3Y_max---4.365--------
Intrinsic Value_3Y_min---8.011--------
Intrinsic Value_5Y_max---7.947--------
Intrinsic Value_5Y_min---14.850--------
Market Cap48907434.000+34%32441112.00023747139.750+37%15715506.870+106%20173517.786+61%23492771.940+38%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-3.663-51%-2.430-12.497+414%1.010-340%-1.425-41%1.161-309%
Pe Ratio-0.890-51%-0.591-0.645+9%-0.544-8%-1.023+73%-0.706+19%
Price Per Share3.980+34%2.6401.933+37%1.279+106%1.642+61%1.912+38%
Price To Free Cash Flow Ratio-1.411-51%-0.936-0.760-19%-0.635-32%-1.183+26%-2.084+123%
Price To Total Gains Ratio-3.795-51%-2.518-0.029-99%-2.294-9%-2.883+15%0.300-940%
Quick Ratio--1.1531.842-37%5.672-80%6.211-81%4.718-76%
Return On Assets---0.637-0.701+10%-0.261-59%-0.316-50%-0.274-57%
Return On Equity----0.4050%-0.3460%-0.3100%-0.3850%
Total Gains Per Share---1.049-0.531-49%-0.526-50%-0.114-89%-0.029-97%
Usd Book Value---13352838.0002255534.500-692%23299724.250-157%19559962.300-168%13212009.100-201%
Usd Book Value Change Per Share---1.049-0.531-49%-0.526-50%-0.123-88%-0.036-97%
Usd Book Value Per Share---1.0870.184-692%1.896-157%1.592-168%1.075-201%
Usd Dividend Per Share----0%-0%0.009-100%0.008-100%
Usd Eps---1.118-0.761-32%-0.555-50%-0.472-58%-0.338-70%
Usd Free Cash Flow---8665167.000-7727043.750-11%-5639851.000-35%-5018872.050-42%-3715798.075-57%
Usd Free Cash Flow Per Share---0.705-0.629-11%-0.459-35%-0.408-42%-0.302-57%
Usd Free Cash Flow To Equity Per Share--1.1260.024+4507%-0.263+123%0.130+769%0.085+1223%
Usd Market Cap48907434.000+34%32441112.00023747139.750+37%15715506.870+106%20173517.786+61%23492771.940+38%
Usd Price Per Share3.980+34%2.6401.933+37%1.279+106%1.642+61%1.912+38%
Usd Profit---13732350.000-9406474.250-32%-6824796.250-50%-5807200.450-58%-4071200.200-70%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---1.049-0.531-49%-0.526-50%-0.114-89%-0.029-97%
 EOD+6 -2MRQTTM+8 -20YOY+9 -195Y+8 -2210Y+7 -23

4.2. Fundamental Score

Let's check the fundamental score of Cellectar Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.890
Price to Book Ratio (EOD)Between0-1-3.663
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.153
Current Ratio (MRQ)Greater than11.221
Debt to Asset Ratio (MRQ)Less than11.620
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.637
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Cellectar Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.961
Ma 20Greater thanMa 503.824
Ma 50Greater thanMa 1003.695
Ma 100Greater thanMa 2003.135
OpenGreater thanClose3.830
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Total Other Income Expense Net 4143147-23124-5173-4,392-4,319



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets21,551
Total Liabilities34,904
Total Stockholder Equity-13,353
 As reported
Total Liabilities 34,904
Total Stockholder Equity+ -13,353
Total Assets = 21,551

Assets

Total Assets21,551
Total Current Assets20,110
Long-term Assets1,441
Total Current Assets
Cash And Cash Equivalents 18,986
Other Current Assets 1,123
Total Current Assets  (as reported)20,110
Total Current Assets  (calculated)20,110
+/-0
Long-term Assets
Property Plant Equipment 1,411
Long-term Assets Other 30
Long-term Assets  (as reported)1,441
Long-term Assets  (calculated)1,441
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities16,471
Long-term Liabilities18,433
Total Stockholder Equity-13,353
Total Current Liabilities
Short-term Debt 56
Accounts payable 7,815
Other Current Liabilities 16,415
Total Current Liabilities  (as reported)16,471
Total Current Liabilities  (calculated)24,285
+/- 7,815
Long-term Liabilities
Capital Lease Obligations 569
Long-term Liabilities  (as reported)18,433
Long-term Liabilities  (calculated)569
+/- 17,864
Total Stockholder Equity
Common Stock0
Retained Earnings -210,034
Accumulated Other Comprehensive Income -17,920
Other Stockholders Equity 213,219
Total Stockholder Equity (as reported)-13,353
Total Stockholder Equity (calculated)-14,735
+/- 1,382
Other
Capital Stock1,382
Cash and Short Term Investments 18,986
Common Stock Shares Outstanding 11,309
Current Deferred Revenue-7,815
Liabilities and Stockholders Equity 21,551
Net Debt -18,417
Net Invested Capital -14,735
Net Working Capital 3,639
Property Plant and Equipment Gross 1,411
Short Long Term Debt Total 569



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-31
> Total Assets 
0
2,026
5,689
4,939
17,896
16,603
14,330
11,923
9,633
20,544
15,676
11,108
6,715
5,754
4,463
1,466
7,130
4,655
5,996
8,932
5,794
3,504
3,492
2,461
2,461
8,431
6,995
10,563
8,649
11,851
10,389
11,478
14,312
12,125
9,647
6,816
8,040
5,889
15,720
13,420
10,911
8,580
6,462
7,596
5,570
11,378
9,296
15,325
15,297
12,601
9,871
12,871
9,561
6,997
19,541
15,054
12,549
19,136
15,659
12,251
8,690
23,853
20,697
58,659
55,065
47,738
41,953
37,202
31,990
25,892
19,320
21,590
14,838
6,509
21,551
21,5516,50914,83821,59019,32025,89231,99037,20241,95347,73855,06558,65920,69723,8538,69012,25115,65919,13612,54915,05419,5416,9979,56112,8719,87112,60115,29715,3259,29611,3785,5707,5966,4628,58010,91113,42015,7205,8898,0406,8169,64712,12514,31211,47810,38911,8518,64910,5636,9958,4312,4612,4613,4923,5045,7948,9325,9964,6557,1301,4664,4635,7546,71511,10815,67620,5449,63311,92314,33016,60317,8964,9395,6892,0260
   > Total Current Assets 
0
2,006
5,658
4,802
17,821
16,566
14,293
11,889
9,598
20,496
15,625
11,060
6,658
5,700
4,403
1,392
7,063
4,579
5,927
8,872
5,762
3,475
3,466
2,436
2,436
3,479
2,109
5,816
4,026
7,340
5,989
5,130
8,109
6,031
5,495
2,768
4,075
2,016
11,921
9,698
7,256
5,007
2,973
4,181
2,245
8,139
6,139
12,193
12,187
9,338
6,687
10,939
7,645
5,016
17,114
13,952
11,093
18,183
14,752
11,386
7,863
23,044
19,803
57,940
54,402
47,125
41,393
36,571
31,395
25,285
18,761
20,530
13,846
5,610
20,110
20,1105,61013,84620,53018,76125,28531,39536,57141,39347,12554,40257,94019,80323,0447,86311,38614,75218,18311,09313,95217,1145,0167,64510,9396,6879,33812,18712,1936,1398,1392,2454,1812,9735,0077,2569,69811,9212,0164,0752,7685,4956,0318,1095,1305,9897,3404,0265,8162,1093,4792,4362,4363,4663,4755,7628,8725,9274,5797,0631,3924,4035,7006,65811,06015,62520,4969,59811,88914,29316,56617,8214,8025,6582,0060
       Cash And Cash Equivalents 
0
1,980
4,830
4,267
17,363
16,110
11,711
9,938
7,772
19,287
15,271
9,742
6,501
5,524
4,206
1,262
6,974
4,493
5,567
8,770
5,612
3,395
3,366
2,373
2,373
3,313
1,591
5,506
3,788
7,146
5,598
4,678
7,862
5,828
5,110
2,418
3,808
1,626
11,576
9,423
7,030
4,833
2,473
3,858
1,908
7,922
5,646
11,445
11,238
8,313
5,662
10,006
6,820
4,181
16,373
13,256
10,488
16,850
13,302
10,615
7,092
22,450
18,842
57,165
53,627
46,778
40,345
35,704
30,634
24,806
17,785
19,866
12,683
5,153
18,986
18,9865,15312,68319,86617,78524,80630,63435,70440,34546,77853,62757,16518,84222,4507,09210,61513,30216,85010,48813,25616,3734,1816,82010,0065,6628,31311,23811,4455,6467,9221,9083,8582,4734,8337,0309,42311,5761,6263,8082,4185,1105,8287,8624,6785,5987,1463,7885,5061,5913,3132,3732,3733,3663,3955,6128,7705,5674,4936,9741,2624,2065,5246,5019,74215,27119,2877,7729,93811,71116,11017,3634,2674,8301,9800
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
555
0
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
55
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000555555555555555555555555555555555555555555555555555555555555055500000000000000000000000
       Net Receivables 
0
13
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000000130
       Other Current Assets 
0
13
828
535
458
456
2,582
1,950
25
1,209
354
1,318
57
176
196
130
88
86
360
103
150
80
100
51
64
58
159
310
238
194
391
453
247
202
384
350
267
390
345
276
226
174
500
323
336
217
493
749
948
1,025
1,025
933
825
781
686
641
605
1,334
1,450
771
771
594
961
774
775
347
1,048
867
760
480
976
663
1,164
457
1,123
1,1234571,1646639764807608671,0483477757749615947717711,4501,3346056416867818259331,0251,025948749493217336323500174226276345390267350384202247453391194238310159586451100801501033608688130196176571,3183541,209251,9502,582456458535828130
   > Long-term Assets 
0
21
31
137
75
37
37
35
35
48
52
48
57
54
61
74
68
76
69
59
32
29
27
0
24
4,952
4,886
4,747
4,623
4,510
4,400
6,348
6,203
6,094
4,152
4,048
3,965
3,873
3,799
3,721
3,656
3,573
3,489
3,416
3,325
3,239
3,157
3,131
3,111
3,264
3,184
1,932
1,916
1,981
2,426
1,102
1,456
952
907
865
826
809
894
720
663
613
560
630
596
607
558
1,060
992
900
1,441
1,4419009921,0605586075966305606136637208948098268659079521,4561,1022,4261,9811,9161,9323,1843,2643,1113,1313,1573,2393,3253,4163,4893,5733,6563,7213,7993,8733,9654,0484,1526,0946,2036,3484,4004,5104,6234,7474,8864,9522402729325969766874615457485248353537377513731210
       Property Plant Equipment 
0
5
22
23
23
21
26
24
24
33
36
33
42
39
45
58
52
61
54
44
17
14
11
3,510
9
3,249
3,184
3,045
2,920
2,808
2,698
2,645
2,622
2,513
2,450
2,361
2,277
2,185
2,111
2,034
1,969
1,886
1,801
1,728
1,638
1,551
1,464
1,444
1,423
1,576
1,497
245
229
212
192
543
909
871
826
784
745
728
675
638
582
532
479
549
514
526
477
979
923
870
1,411
1,4118709239794775265145494795325826386757287457848268719095431922122292451,4971,5761,4231,4441,4641,5511,6381,7281,8011,8861,9692,0342,1112,1852,2772,3612,4502,5132,6222,6452,6982,8082,9203,0453,1843,24993,51011141744546152584539423336332424262123232250
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6751,6750000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
541
541
541
75
75
75
81
81
219
75
75
75
0
0
0
0
0
0
0
0
0
0000000007575752198181757575541541541000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,675
1,675
1,675
1,675
1,676
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,675
1,676
1,676
1,675
1,675
1,675
1,675
1,675
1,676
1,675
1,676
1,675
1,675
1,675
1,675
1,675
1,675
1,676
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,6761,6751,6751,6751,6751,6751,6751,6761,6751,6761,6751,6751,6751,6751,6751,6761,6761,6751,6751,6751,6751,6751,6751,6751,6751,6761,6751,6751,6751,6750000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
15
1,702
1,702
1,702
1,702
1,703
1,702
3,702
3,581
3,580
1,702
1,687
1,688
1,687
1,688
1,688
1,687
1,687
1,687
1,687
1,687
1,688
1,693
1,688
1,687
1,687
1,687
1,687
12
93
559
559
547
81
81
81
81
81
219
81
364
81
81
81
81
81
81
81
0
0
0
0008181818181818136481219818181818154755955993121,6871,6871,6871,6871,6881,6931,6881,6871,6871,6871,6871,6871,6881,6881,6871,6881,6871,7023,5803,5813,7021,7021,7031,7021,7021,7021,702151200000000000000000000000
> Total Liabilities 
114
865
696
217
476
635
1,108
1,313
1,307
12,835
4,753
16,978
20,001
22,593
21,308
7,051
5,367
29,989
28,199
35,827
20,028
19,605
20,510
1,254
1,254
1,023
1,098
1,082
1,087
1,219
1,322
1,320
7,181
6,681
5,221
5,116
8,767
8,429
2,570
2,674
6,323
6,207
5,781
5,947
2,993
1,549
1,579
1,785
1,548
1,737
2,279
2,117
2,109
2,290
2,661
1,793
2,702
3,150
3,428
3,191
3,444
3,867
4,473
3,865
5,289
3,755
3,368
4,157
4,781
5,698
6,569
6,082
7,504
6,976
34,904
34,9046,9767,5046,0826,5695,6984,7814,1573,3683,7555,2893,8654,4733,8673,4443,1913,4283,1502,7021,7932,6612,2902,1092,1172,2791,7371,5481,7851,5791,5492,9935,9475,7816,2076,3232,6742,5708,4298,7675,1165,2216,6817,1811,3201,3221,2191,0871,0821,0981,0231,2541,25420,51019,60520,02835,82728,19929,9895,3677,05121,30822,59320,00116,9784,75312,8351,3071,3131,108635476217696865114
   > Total Current Liabilities 
114
852
696
217
476
635
1,108
1,313
1,307
2,916
4,753
7,059
9,624
8,239
6,962
6,617
4,942
7,899
7,409
16,968
5,866
5,451
6,365
887
887
449
522
504
506
636
737
733
6,593
6,091
4,629
4,523
4,408
4,078
2,065
2,185
5,896
5,840
5,476
5,703
2,812
1,394
1,426
1,633
1,398
1,589
2,133
2,115
2,108
2,289
2,661
1,622
2,200
2,674
2,978
2,770
3,051
3,320
3,956
3,563
5,020
3,518
3,166
3,990
4,651
5,606
6,515
5,529
6,956
6,445
16,471
16,4716,4456,9565,5296,5155,6064,6513,9903,1663,5185,0203,5633,9563,3203,0512,7702,9782,6742,2001,6222,6612,2892,1082,1152,1331,5891,3981,6331,4261,3942,8125,7035,4765,8405,8962,1852,0654,0784,4084,5234,6296,0916,5937337376365065045224498878876,3655,4515,86616,9687,4097,8994,9426,6176,9628,2399,6247,0594,7532,9161,3071,3131,108635476217696852114
       Short-term Debt 
55
500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,149
2,932
4,066
5,054
0
0
2
2
2
2
2
2
2
2
2
2
2
1
42
105
122
183
243
245
246
247
211
151
89
3
3
3
3
3
3
3
2
98
100
103
106
109
113
116
120
124
127
131
135
140
144
148
51
51
54
56
5654515114814414013513112712412011611310910610310098233333338915121124724624524318312210542122222222222005,0544,0662,9323,1490000000000000000050055
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
120
0
0
0
244
0
0
0
87
212
7
6
5
5
4
0
0
96
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000096004556721287000244000120000000000000000000000000000000000000000
       Accounts payable 
58
192
690
211
470
630
1,102
1,088
1,245
2,566
4,546
6,372
8,546
7,505
5,620
0
0
0
0
3,299
2,895
1,352
771
393
566
366
442
478
472
608
713
717
863
1,021
1,157
1,162
992
1,195
1,140
934
824
712
580
676
609
817
1,087
1,416
1,186
1,466
2,019
1,868
1,884
2,094
2,572
612
2,055
2,528
2,875
1,278
2,941
3,207
3,839
1,429
1,429
3,391
3,034
1,415
4,512
5,462
6,367
2,558
6,905
6,392
7,815
7,8156,3926,9052,5586,3675,4624,5121,4153,0343,3911,4291,4293,8393,2072,9411,2782,8752,5282,0556122,5722,0941,8841,8682,0191,4661,1861,4161,0878176096765807128249341,1401,1959921,1621,1571,0218637177136084724784423665663937711,3522,8953,29900005,6207,5058,5466,3724,5462,5661,2451,0881,10263047021169019258
       Other Current Liabilities 
1
147
6
6
6
6
6
225
62
351
207
687
1,045
700
1,308
6,584
4,909
7,866
7,375
10,487
5
0
507
305
288
82
78
23
504
633
734
13
5,727
5,067
4,627
4,521
4,407
4,036
1,960
2,062
5,713
5,597
5,231
5,457
2,565
1,182
1,275
1,544
1,396
1,586
2,130
2,112
2,105
2,286
2,658
43
2,102
2,574
2,875
0
2,941
3,207
3,839
0
4,896
3,391
3,034
0
4,512
5,462
6,367
2,920
6,905
6,392
16,415
16,4156,3926,9052,9206,3675,4624,51203,0343,3914,89603,8393,2072,94102,8752,5742,102432,6582,2862,1052,1122,1301,5861,3961,5441,2751,1822,5655,4575,2315,5975,7132,0621,9604,0364,4074,5214,6275,0675,727137346335042378822883055070510,4877,3757,8664,9096,5841,3087001,04568720735162225666661471
   > Long-term Liabilities 
0
13
0
0
0
0
0
0
0
9,919
9,919
9,919
10,377
14,354
14,346
433
425
22,089
20,790
18,860
14,162
14,153
14,145
0
367
574
576
578
581
583
586
587
589
590
592
593
4,360
4,351
505
489
428
367
306
244
181
155
154
152
150
148
146
2
1
1
0
171
502
476
450
422
393
548
517
302
269
236
202
166
130
92
54
553
548
531
18,433
18,433531548553549213016620223626930251754839342245047650217101121461481501521541551812443063674284895054,3514,360593592590589587586583581578576574367014,14514,15314,16218,86020,79022,08942543314,34614,35410,3779,9199,9199,9190000000130
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
455
455
0
0
0
0
0
0
0
0
450
4,215
0
358
341
279
218
157
95
32
7
6
5
5
4
3
2
0
1
0
0
0
0
0
0
0
184
184
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001841840000000102345567329515721827934135804,215450000000004554550000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115
358
118
121
124
127
130
133
135
137
140
142
143
144
146
147
148
148
149
149
148
149
148
148
147
145
144
143
0
0
0
0
171
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000171000014314414514714814814914814914914814814714614414314214013713513313012712412111835811500000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
118
121
0
0
0
0
0
0
0
0
143
145
0
147
148
148
149
149
149
149
148
148
147
145
144
143
0
0
0
0
171
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000017100001431441451471481481491491491491481481470145143000000001211180000000000000000000000000
> Total Stockholder Equity
-114
1,162
4,994
4,722
17,421
15,967
13,223
10,610
8,326
7,709
10,924
-5,870
-13,286
-16,839
-16,844
-5,585
1,763
-25,334
-22,202
-26,896
-14,233
-16,101
-17,018
134
1,207
7,408
5,897
9,481
7,561
10,632
9,067
10,158
7,131
5,444
4,426
1,700
-727
-2,541
13,150
10,746
4,588
2,373
680
1,650
2,577
9,829
7,717
13,540
13,749
10,865
7,593
10,754
7,452
4,707
16,880
13,261
9,847
15,985
12,231
9,059
5,246
19,985
16,224
54,795
49,776
43,983
38,585
33,045
27,209
20,194
12,751
15,508
7,334
-467
-13,353
-13,353-4677,33415,50812,75120,19427,20933,04538,58543,98349,77654,79516,22419,9855,2469,05912,23115,9859,84713,26116,8804,7077,45210,7547,59310,86513,74913,5407,7179,8292,5771,6506802,3734,58810,74613,150-2,541-7271,7004,4265,4447,13110,1589,06710,6327,5619,4815,8977,4081,207134-17,018-16,101-14,233-26,896-22,202-25,3341,763-5,585-16,844-16,839-13,286-5,87010,9247,7098,32610,61013,22315,96717,4214,7224,9941,162-114
   Common Stock
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
0
5
0
0
0
0
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0000001111100000000000000000000000000011111000000050111110000000000000000011
   Retained Earnings -210,034-196,302-188,080-179,499-172,284-164,473-157,038-150,898-144,980-139,161-133,133-126,775-123,160-119,251-115,639-111,681-108,301-104,398-101,210-97,588-93,761-90,746-87,825-84,349-80,271-76,800-73,678-70,787-68,202-65,915-63,782-64,607-65,558-63,699-61,413-59,166-56,595-56,089-54,003-51,060-47,111-45,796-43,731-40,277-38,120-36,068-33,837-31,480-29,515-27,605-73,977-73,977-73,379-72,153-70,722-76,072-63,212-60,469-55,612-59,693-57,554-55,019-50,343-43,242-36,703-30,288-26,066-23,685-21,012-18,210-16,753-15,399-14,694-13,739-129
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,013
35,411
0
0
0
0
0
0
0
0
52,759
53,275
53,548
65,642
65,809
66,001
66,073
66,238
66,256
66,359
75,744
75,918
83,451
87,427
87,664
87,863
94,108
94,640
95,453
107,127
108,323
109,268
119,235
119,384
119,592
119,737
138,088
138,236
161,534
171,161
174,506
0
0
0
0
0
0
0
0
0
000000000174,506171,161161,534138,236138,088119,737119,592119,384119,235109,268108,323107,12795,45394,64094,10887,86387,66487,42783,45175,91875,74466,35966,25666,23866,07366,00165,80965,64253,54853,27552,7590000000035,41135,0130000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
5
14,900
19,687
20,120
34,173
34,177
34,234
34,294
34,391
37,996
37,707
37,371
37,057
38,180
40,709
40,204
35,702
35,135
41,009
49,176
56,488
56,051
56,360
0
75,179
35,013
35,411
40,961
41,398
46,699
47,187
50,435
50,861
51,239
51,537
52,759
53,275
53,548
69,744
69,912
66,001
66,073
66,238
66,256
66,359
75,744
75,918
83,451
87,427
87,664
87,863
94,108
94,640
95,453
107,127
108,323
109,268
119,235
119,384
119,592
119,737
138,088
138,236
161,534
171,161
174,506
182,182
182,560
182,864
183,285
183,652
193,624
194,033
195,834
213,219
213,219195,834194,033193,624183,652183,285182,864182,560182,182174,506171,161161,534138,236138,088119,737119,592119,384119,235109,268108,323107,12795,45394,64094,10887,86387,66487,42783,45175,91875,74466,35966,25666,23866,07366,00169,91269,74453,54853,27552,75951,53751,23950,86150,43547,18746,69941,39840,96135,41135,01375,179056,36056,05156,48849,17641,00935,13535,70240,20440,70938,18037,05737,37137,70737,99634,39134,29434,23434,17734,17320,12019,68714,9005



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-33,835
Operating Income-33,835-33,835
 
Operating Expense (+$)
Research Development25,729
Selling General Administrative8,107
Selling And Marketing Expenses-
Operating Expense33,83533,835
 
Net Interest Income (+$)
Interest Income395
Interest Expense--
Other Finance Cost-0
Net Interest Income395
 
Pretax Income (+$)
Operating Income-33,835
Net Interest Income395
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-37,810-33,835
EBIT - interestExpense = 0
-37,750
-37,750
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--37,810
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-37,810
Tax Provision--
Net Income From Continuing Ops-37,750-37,810
Net Income-37,750
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--395
 

Technical Analysis of Cellectar
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cellectar. The general trend of Cellectar is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cellectar's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cellectar Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.45 < 5.19 < 6.641.

The bearish price targets are: 3.35 > 3.24 > 3.15.

Tweet this
Cellectar Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cellectar Biosciences Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cellectar Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cellectar Biosciences Inc. The current macd is 0.05355582.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellectar price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cellectar. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cellectar price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cellectar Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartCellectar Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cellectar Biosciences Inc. The current adx is 29.21.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cellectar shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Cellectar Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cellectar Biosciences Inc. The current sar is 3.45831836.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cellectar Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cellectar Biosciences Inc. The current rsi is 55.96. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Cellectar Biosciences Inc Daily Relative Strength Index (RSI) ChartCellectar Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cellectar Biosciences Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellectar price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cellectar Biosciences Inc Daily Stochastic Oscillator ChartCellectar Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cellectar Biosciences Inc. The current cci is 34.54.

Cellectar Biosciences Inc Daily Commodity Channel Index (CCI) ChartCellectar Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cellectar Biosciences Inc. The current cmo is 14.96.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cellectar Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartCellectar Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cellectar Biosciences Inc. The current willr is -23.17073171.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cellectar is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cellectar Biosciences Inc Daily Williams %R ChartCellectar Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cellectar Biosciences Inc.

Cellectar Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cellectar Biosciences Inc. The current atr is 0.28428254.

Cellectar Biosciences Inc Daily Average True Range (ATR) ChartCellectar Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cellectar Biosciences Inc. The current obv is 69,264,805.

Cellectar Biosciences Inc Daily On-Balance Volume (OBV) ChartCellectar Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cellectar Biosciences Inc. The current mfi is 49.51.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cellectar Biosciences Inc Daily Money Flow Index (MFI) ChartCellectar Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cellectar Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Cellectar Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cellectar Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.961
Ma 20Greater thanMa 503.824
Ma 50Greater thanMa 1003.695
Ma 100Greater thanMa 2003.135
OpenGreater thanClose3.830
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cellectar with someone you think should read this too:
  • Are you bullish or bearish on Cellectar? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cellectar? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cellectar Biosciences Inc

I send you an email if I find something interesting about Cellectar Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cellectar Biosciences Inc.

Receive notifications about Cellectar Biosciences Inc in your mailbox!